Loading...

Genomed Spólka Akcyjna

WSE:GEN
Snowflake Description

Flawless balance sheet with proven track record.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
GEN
WSE
PLN28M
Market Cap
  1. Home
  2. PL
  3. Pharmaceuticals & Biotech
Company description

Genomed Spólka Akcyjna provides DNA analysis and congenital diseases diagnostic services in Poland. The last earnings update was 95 days ago. More info.


Add to Portfolio Compare Print
GEN Share Price and Events
7 Day Returns
-6.3%
WSE:GEN
0.9%
PL Biotechs
-0.9%
PL Market
1 Year Returns
13.5%
WSE:GEN
-24.3%
PL Biotechs
-7.4%
PL Market
GEN Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Genomed Spólka Akcyjna (GEN) -6.3% -9.5% -13.2% 13.5% 11.8% 467.6%
PL Biotechs 0.9% -9.6% -0.1% -24.3% -31.3% 5.5%
PL Market -0.9% -7.1% -6.3% -7.4% 9.6% -11.5%
1 Year Return vs Industry and Market
  • GEN outperformed the Biotechs industry which returned -24.3% over the past year.
  • GEN outperformed the Market in Poland which returned -7.4% over the past year.
Price Volatility
GEN
Industry
5yr Volatility vs Market

Value

 Is Genomed Spólka Akcyjna undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Genomed Spólka Akcyjna to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Genomed Spólka Akcyjna.

WSE:GEN Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Extrapolated from most recent financials. See below
Discount Rate (Cost of Equity) See below 11.8%
Perpetual Growth Rate 10-Year PL Government Bond Rate 2.9%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for WSE:GEN
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year PL Govt Bond Rate 2.9%
Equity Risk Premium S&P Global 7.1%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.38
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.381 (1 + (1- 19%) (0%))
1.256
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.26
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 2.85% + (1.256 * 7.14%)
11.81%

Discounted Cash Flow Calculation for WSE:GEN using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Genomed Spólka Akcyjna is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

WSE:GEN DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (PLN, Millions) Source Present Value
Discounted (@ 11.81%)
2019 0.28 Est @ 55.61% 0.25
2020 0.39 Est @ 39.78% 0.31
2021 0.50 Est @ 28.7% 0.36
2022 0.61 Est @ 20.95% 0.39
2023 0.71 Est @ 15.52% 0.40
2024 0.79 Est @ 11.72% 0.40
2025 0.86 Est @ 9.06% 0.39
2026 0.92 Est @ 7.19% 0.38
2027 0.98 Est @ 5.89% 0.36
2028 1.02 Est @ 4.98% 0.34
Present value of next 10 years cash flows PLN3.59
WSE:GEN DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= PLN1.02 × (1 + 2.85%) ÷ (11.81% – 2.85%)
PLN11.75
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= PLN11.75 ÷ (1 + 11.81%)10
PLN3.85
WSE:GEN Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= PLN3.59 + PLN3.85
PLN7.43
Equity Value per Share
(PLN)
= Total value / Shares Outstanding
= PLN7.43 / 1.32
PLN5.62
WSE:GEN Discount to Share Price
Calculation Result
Value per share (PLN) From above. PLN5.62
Current discount Discount to share price of PLN21.00
= -1 x (PLN21.00 - PLN5.62) / PLN5.62
-273.4%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of Genomed Spólka Akcyjna is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Genomed Spólka Akcyjna's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Genomed Spólka Akcyjna's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
WSE:GEN PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in PLN PLN1.15
WSE:GEN Share Price ** WSE (2019-05-20) in PLN PLN21
Europe Biotechs Industry PE Ratio Median Figure of 29 Publicly-Listed Biotechs Companies 22.03x
Poland Market PE Ratio Median Figure of 463 Publicly-Listed Companies 10.7x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Genomed Spólka Akcyjna.

WSE:GEN PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= WSE:GEN Share Price ÷ EPS (both in PLN)

= 21 ÷ 1.15

18.21x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Genomed Spólka Akcyjna is good value based on earnings compared to the Europe Biotechs industry average.
  • Genomed Spólka Akcyjna is overvalued based on earnings compared to the Poland market.
Price based on expected Growth
Does Genomed Spólka Akcyjna's expected growth come at a high price?
Raw Data
WSE:GEN PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 18.21x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
12.3%per year
Europe Biotechs Industry PEG Ratio Median Figure of 23 Publicly-Listed Biotechs Companies 1.29x
Poland Market PEG Ratio Median Figure of 113 Publicly-Listed Companies 0.93x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Genomed Spólka Akcyjna, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Genomed Spólka Akcyjna's assets?
Raw Data
WSE:GEN PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in PLN PLN5.74
WSE:GEN Share Price * WSE (2019-05-20) in PLN PLN21
Poland Biotechs Industry PB Ratio Median Figure of 8 Publicly-Listed Biotechs Companies 1.84x
Poland Market PB Ratio Median Figure of 689 Publicly-Listed Companies 0.97x
WSE:GEN PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= WSE:GEN Share Price ÷ Book Value per Share (both in PLN)

= 21 ÷ 5.74

3.66x

* Primary Listing of Genomed Spólka Akcyjna.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Genomed Spólka Akcyjna is overvalued based on assets compared to the PL Biotechs industry average.
X
Value checks
We assess Genomed Spólka Akcyjna's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Genomed Spólka Akcyjna has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Genomed Spólka Akcyjna expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

  • No analysts cover Genomed Spólka Akcyjna, future earnings growth has been estimated based on fundamentals.
The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
12.3%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Genomed Spólka Akcyjna expected to grow at an attractive rate?
  • Genomed Spólka Akcyjna's earnings growth is expected to exceed the low risk savings rate of 2.9%.
Growth vs Market Checks
  • Genomed Spólka Akcyjna's earnings growth is expected to exceed the Poland market average.
  • Unable to compare Genomed Spólka Akcyjna's revenue growth to the Poland market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
WSE:GEN Future Growth Rates Data Sources
Data Point Source Value (per year)
WSE:GEN Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts 12.3%
Europe Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 20%
Europe Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 14.3%
Poland Market Earnings Growth Rate Market Cap Weighted Average 10%
Poland Market Revenue Growth Rate Market Cap Weighted Average 5.5%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
WSE:GEN Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in PLN Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
WSE:GEN Past Financials Data
Date (Data in PLN Millions) Revenue Cash Flow Net Income *
2018-12-31 19 1 2
2018-09-30 18 2 2
2018-06-30 17 2 2
2018-03-31 17 1 2
2017-12-31 16 1 2
2017-09-30 16 0 1
2017-06-30 16 0 1
2017-03-31 15 1 0
2016-12-31 14 1 0
2016-09-30 14 -1 1
2016-06-30 12 0 1
2016-03-31 11 1 0

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Genomed Spólka Akcyjna's earnings are expected to grow by 12.3% yearly, however this is not considered high growth (20% yearly).
  • Unable to determine if Genomed Spólka Akcyjna is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
WSE:GEN Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Genomed Spólka Akcyjna Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

WSE:GEN Past Financials Data
Date (Data in PLN Millions) EPS *
2018-12-31 1.15
2018-09-30 1.30
2018-06-30 1.69
2018-03-31 1.70
2017-12-31 1.36
2017-09-30 0.73
2017-06-30 0.51
2017-03-31 0.20
2016-12-31 0.21
2016-09-30 0.65
2016-06-30 0.55
2016-03-31 0.27

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Genomed Spólka Akcyjna will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Genomed Spólka Akcyjna's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Europe market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Europe market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Genomed Spólka Akcyjna has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Genomed Spólka Akcyjna performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Genomed Spólka Akcyjna's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Genomed Spólka Akcyjna has delivered over 20% year on year earnings growth in the past 5 years.
  • Genomed Spólka Akcyjna's 1-year earnings growth is negative, it can't be compared to the 5-year average.
  • Genomed Spólka Akcyjna's 1-year earnings growth is negative, it can't be compared to the Europe Biotechs industry average.
Earnings and Revenue History
Genomed Spólka Akcyjna's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Genomed Spólka Akcyjna Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

WSE:GEN Past Revenue, Cash Flow and Net Income Data
Date (Data in PLN Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 18.59 1.52 9.60
2018-09-30 18.05 1.72 8.76
2018-06-30 17.43 2.23 8.19
2018-03-31 17.05 2.25 8.20
2017-12-31 16.36 1.80 8.31
2017-09-30 15.86 0.97 8.68
2017-06-30 15.60 0.67 8.93
2017-03-31 15.35 0.27 9.06
2016-12-31 14.39 0.27 8.51
2016-09-30 13.54 0.86 7.63
2016-06-30 12.15 0.73 7.11
2016-03-31 10.76 0.36 6.89
2015-12-31 9.68 0.00 6.99
2015-09-30 8.78 -0.26 7.01
2015-06-30 8.39 -0.45 7.34
2015-03-31 7.70 -0.10 6.50
2014-12-31 7.33 0.21 5.97
2014-09-30 6.32 -0.03 5.80
2014-06-30 5.62 0.03 4.87
2014-03-31 5.33 -0.15 4.76
2013-12-31 4.96 -0.32 4.38
2013-09-30 4.98 -0.37 3.89
2013-06-30 5.12 -0.53 5.79
2013-03-31 5.51 -0.25 4.80
2012-12-31 5.53 -0.37 3.87
2012-09-30 5.63 -0.13 5.96
2012-06-30 5.43 0.20 3.15

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Genomed Spólka Akcyjna has efficiently used shareholders’ funds last year (Return on Equity greater than 20%).
  • Genomed Spólka Akcyjna used its assets more efficiently than the Europe Biotechs industry average last year based on Return on Assets.
  • Genomed Spólka Akcyjna has significantly improved its use of capital last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess Genomed Spólka Akcyjna's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Genomed Spólka Akcyjna has a total score of 4/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Genomed Spólka Akcyjna's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Genomed Spólka Akcyjna's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Genomed Spólka Akcyjna is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Genomed Spólka Akcyjna's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Genomed Spólka Akcyjna's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Genomed Spólka Akcyjna has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Genomed Spólka Akcyjna Company Filings, last reported 4 months ago.

WSE:GEN Past Debt and Equity Data
Date (Data in PLN Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 7.58 0.00 3.62
2018-09-30 7.06 0.00 2.53
2018-06-30 7.06 0.00 2.94
2018-03-31 6.68 0.00 3.72
2017-12-31 6.05 0.00 3.11
2017-09-30 5.34 0.00 2.44
2017-06-30 4.83 0.00 2.94
2017-03-31 4.53 0.00 3.64
2016-12-31 4.25 0.00 2.75
2016-09-30 4.37 0.00 2.28
2016-06-30 4.16 0.00 2.41
2016-03-31 4.16 0.00 2.29
2015-12-31 3.98 0.00 2.68
2015-09-30 3.51 0.01 1.97
2015-06-30 3.43 0.00 1.04
2015-03-31 3.80 0.00 2.03
2014-12-31 3.98 0.00 2.97
2014-09-30 3.77 0.07 2.22
2014-06-30 3.88 0.00 2.86
2014-03-31 3.92 0.00 3.04
2013-12-31 3.80 0.00 1.30
2013-09-30 3.83 0.00 2.25
2013-06-30 3.88 0.00 3.19
2013-03-31 4.08 0.00 3.09
2012-12-31 4.11 0.00 2.72
2012-09-30 4.20 0.00 2.72
2012-06-30 4.41 0.00 1.22
  • Genomed Spólka Akcyjna has no debt.
  • Genomed Spólka Akcyjna had no debt 5 years ago.
  • Genomed Spólka Akcyjna has no debt, it does not need to be covered by operating cash flow.
  • Genomed Spólka Akcyjna has no debt, therefore coverage of interest payments is not a concern.
X
Financial health checks
We assess Genomed Spólka Akcyjna's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Genomed Spólka Akcyjna has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Genomed Spólka Akcyjna's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Genomed Spólka Akcyjna dividends.
If you bought PLN2,000 of Genomed Spólka Akcyjna shares you are expected to receive PLN0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Genomed Spólka Akcyjna's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Genomed Spólka Akcyjna's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
WSE:GEN Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.8%
Poland Market Average Dividend Yield Market Cap Weighted Average of 200 Stocks 4.1%
Poland Minimum Threshold Dividend Yield 10th Percentile 1.5%
Poland Bottom 25% Dividend Yield 25th Percentile 2.8%
Poland Top 25% Dividend Yield 75th Percentile 7.9%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Genomed Spólka Akcyjna has not reported any payouts.
  • Unable to verify if Genomed Spólka Akcyjna's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Genomed Spólka Akcyjna's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Genomed Spólka Akcyjna has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Genomed Spólka Akcyjna's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.5%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Genomed Spólka Akcyjna afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Genomed Spólka Akcyjna has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Genomed Spólka Akcyjna's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Anna Boguszewska-Chachulska
CEO Bio

Dr. Hab. Anna Boguszewska-Chachulska, Ph.D. is a Co-founder of Genomed Spólka Akcyjna and has been its Chief Executive Officer since 2013. Dr. Hab. Boguszewska-Chachulska also serves as President of the Management Board at Genomed Spólka Akcyjna. She served as Joint Owner at Genomed Spólka Akcyjna. From 2009 to 2013, she served as Chief Operating Officer and Member of the board of Directors at Genomed Ltd and since 2011 at Genomed SA (joint-stock company). Dr. Hab. Boguszewska-Chachulska co-founded Genomed Ltd. Co in 2007. She served as Member of the Advisory Board Genomed Ltd from 2007 to 2009. Dr. Hab. Boguszewska-Chachulska was Member of Board of Directors of at Genomed Ltd since 2009. From 1996 to 1998, she led a project on plant transformation towards potato virus Y resistance financed by a grant of Polish Committee of Scientific Research. She has research training and experience at Laboratoire de Biologie Cellulaire, INRA, Versailles, France - CNRS stipend, October-December 1992, December 1993; October 1995, 1996, 1997 and EEC grant - April-June 1993, French Government stipend - July-August 1995. Dr. Hab. Boguszewska-Chachulska served as Professor at the Institute of Biotechnology, Department of Chemistry, Warsaw University of Technology from September 2009 to August 2010; Associate Professor at the Institute of Biochemistry and Biophysics since 2008; Assistant Professor at the Institute of Biochemistry and Biophysics from 1998 to 2008; Senior Research Assistant at Institute of Biochemistry and Biophysics from 1993 to 1998 and Research assistant from 1990 to 1993. From 2009 to 2010, she was Tutor of two M.Sc. and three B.Sc. students. Dr. Hab. Boguszewska-Chachulska received Polish Scientific Award of Plant Genetics - First prize for “Creative contribution to the plant molecular virology” on June 30, 1998; Award of Polish Academy of Sciences for co-authoring of a series of works dedicated to “RNA genomes of crop pathogens - structures, functions, control and spread” on November 18 1999; Award of IBB PAS for the review published in Prog. Nucleic Acid Res. Mol. Biol. 80, 135-68. “Virus-Like Particles: Models for Assembly Studies and Foreign Epitope Carriers on March 23 2006 ” and on December 04 2006 Habilitation stipend for Women in Science 2006 awarded by l’Oréal Polska with a support from Polish UNESCO Committee. Dr. Hab. Boguszewska-Chachulska Patents Obtained; P-186760 (1997), New binary vector and method of its construction P-186761 (1997) and Method of construction of plants resistant to potato virus Y (PVY). Dr. Hab. Boguszewska-Chachulska took post-doctoral training in the laboratory of Dr. Linda E. Hyman at Tulane University in New Orleans in U.S. - looking for the roles of Elongin C in yeast from August 1998 to June 2000. She is specialised in Molecular Biology. Dr. Hab. Boguszewska-Chachulska studied (B.Sc) at Biology Faculty, University of Warsaw, from 1984 to 1990; M.Sc.: Department of Genetics, University of Warsaw.; Ph.D. in Biochemistry : Institute of Biochemistry and Biophysics, Polish Academy of Sciences, Warsaw, January 1998; Habilitation in Biology Institute of Biochemistry and Biophysics, Polish Academy of Sciences, Warsaw, October 2008.

CEO Compensation
  • Insufficient data for Anna to compare compensation growth.
  • Insufficient data for Anna to establish whether their remuneration is reasonable compared to companies of similar size in Poland.
Management Team

Anna Boguszewska-Chachulska

TITLE
Co-Founder

Marek Zagulski

TITLE
Co-Founder & Member of Management Board

Andrzej Palucha

TITLE
Co-Founder & Member of Management Board

Tomasz Danis

TITLE
Member of Management Board
TENURE
6 yrs
Board of Directors

Maciej Kowalski

TITLE
Chairman of the Supervisory Board

Piotr Skowron

TITLE
Member of Supervisory Board

Tomasz Bykowski

TITLE
Member of Supervisory Board

Boguslaw Bobula

TITLE
Member of Supervisory Board
AGE
60

Mieczyslaw Prószynski

TITLE
Member of the Supervisory Board
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (PLN) Value (PLN)
X
Management checks
We assess Genomed Spólka Akcyjna's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Genomed Spólka Akcyjna has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Boasting A 32% Return On Equity, Is Genomed Spólka Akcyjna (WSE:GEN) A Top Quality Stock?

Genomed Spólka Akcyjna has a ROE of 32%, based on the last twelve months. … That means that for every PLN1 worth of shareholders' equity, it generated PLN0.32 in profit. … Return on Equity = Net Profit ÷ Shareholders' Equity

Simply Wall St -

Is Genomed Spólka Akcyjna (WSE:GEN) Attractive At Its Current PE Ratio?

Genomed Spólka Akcyjna (WSE:GEN) is trading with a trailing P/E of 12.4x, which is lower than the industry average of 26.6x. … While GEN might seem like an attractive stock to buy, it is important to understand the assumptions behind the P/E ratio before you make any investment decisions. … Check out our latest analysis for Genomed Spólka Akcyjna

Simply Wall St -

Is Genomed Spólka Akcyjna's (WSE:GEN) 33.69% ROE Strong Compared To Its Industry?

Genomed Spólka Akcyjna (WSE:GEN) delivered an ROE of 33.69% over the past 12 months, which is an impressive feat relative to its industry average of 17.03% during the same period. … If GEN borrows debt to invest in its business, its profits will be higher. … But ROE does not capture any debt, so we only see high profits and low equity, which is great on the surface

Simply Wall St -

Does Genomed Spólka Akcyjna's (WSE:GEN) PE Ratio Signal A Buying Opportunity?

By comparing a stock’s price per share to its earnings per share, we are able to see how much investors are paying for each dollar of the company’s earnings. … Formula Price-Earnings Ratio = Price per share ÷ Earnings per share P/E Calculation for GEN Price per share = PLN15.8 Earnings per share = PLN1.34 ∴ Price-Earnings Ratio = PLN15.8 ÷ PLN1.34 = 11.8x On its own, the P/E ratio doesn’t tell you much; however, it becomes extremely useful when you compare it with other similar companies. … Since GEN's P/E of 11.8x is lower than its industry peers (25.4x), it means that investors are paying less than they should for each dollar of GEN's earnings.

Simply Wall St -

What You Must Know About Genomed Spólka Akcyjna's (WSE:GEN) ROE

See our latest analysis for Genomed Spólka Akcyjna What you must know about ROE Firstly, Return on Equity, or ROE, is simply the percentage of last years’ earning against the book value of shareholders’ equity. … Return on Equity = Net Profit ÷ Shareholders Equity ROE is measured against cost of equity in order to determine the efficiency of Genomed Spólka Akcyjna’s equity capital deployed. … Given a positive discrepancy of 20.72% between return and cost, this indicates that Genomed Spólka Akcyjna pays less for its capital than what it generates in return, which is a sign of capital efficiency.

Simply Wall St -

Company Info

Description

Genomed Spólka Akcyjna provides DNA analysis and congenital diseases diagnostic services in Poland. It develops molecular diagnostics based on DNA sequencing for the application of prophylactics and treatment, such as replacement or gene therapy. The company also offers analysis of mutations responsible for congenital diseases in approximately 120 genes; and next generation sequencing technology. In addition, it provides various types of DNA sequence analysis, including polymorphism analysis, and the sequencing of phage genetic material, or bacteria and yeast genomes; and next generation sequencing and genetic counseling services. Further, the company offers DNA oligonucleotides synthesis, RNA oligonucleotides and peptide synthesis, various nucleotide modifications, and the 4LAB automated pipetting workstation, as well as laboratory equipment through the eStore. It serves scientific institutes, universities, hospitals, and biotechnological and pharmaceutical companies, as well as healthcare networks and individual customers. Genomed Spólka Akcyjna is based in Warsaw, Poland.

Details
Name: Genomed Spólka Akcyjna
GEN
Exchange: WSE
Founded:
PLN27,747,321
1,321,301
Website: http://www.genomed.pl
Address: Genomed Spólka Akcyjna
ul. Ponczowa 12,
Warsaw,
02-971,
Poland
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
WSE GEN Bearer Shares Warsaw Stock Exchange PL PLN 30. May 2011
Number of employees
Current staff
Staff numbers
0
Genomed Spólka Akcyjna employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/05/20 21:45
End of day share price update: 2019/05/20 00:00
Last earnings filing: 2019/02/14
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.